However, these drugs are effective against most imatinib-resistant forms of BCR-ABL, except the most refractory gatekeeper T315I mutation, which arises in more than 20% of CML patients12,.13 Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.